Potassium Ion

Potassium Ion

SCHEMBL4705992

Cn1c([S-])nnc1-c1ccccc1.[K+]

nearest known ligand 0.55

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA

The experimentally established mechanism targets of Potassium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 8/20 0.51
DRD2 P14416 1/20 0.47
KMT2A Q03164 2/20 0.47
TSHR P16473 1/20 0.46
MEN1 O00255 1/20 0.44
RXFP1 Q9HBX9 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.42
AVPR1A P37288 1/20 0.42
ALDH1A1 P00352 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL822698 0.83 HSD11B1 (0.68) HSD11B1DRD2KMT2ATSHRL3MBTL1
SCHEMBL889637 0.77 HSD11B1 (0.56) HSD11B1DRD2KMT2ATSHRAVPR1A
SCHEMBL392717 0.73 HSD11B1 (0.53) HSD11B1DRD2KMT2ATSHRL3MBTL1
SCHEMBL13872765 0.73 KMT2A (0.54) HSD11B1DRD2KMT2ATSHRL3MBTL1
SCHEMBL7454054 0.73 HSD11B1 (0.53) HSD11B1DRD2KMT2ATSHRL3MBTL1
Potassium Ion SCHEMBL4705991 0.73 HSD11B1 (0.45) HSD11B1DRD2KMT2ATSHRMEN1
SCHEMBL14425750 0.71 HSD11B1 (0.50) HSD11B1DRD2KMT2ATSHRL3MBTL1
SCHEMBL974759 0.71 ALDH1A1 (0.69) DRD2KMT2ATSHRMEN1L3MBTL1
SCHEMBL19798383 0.71 HSD11B1 (0.50) HSD11B1DRD2KMT2ATSHRL3MBTL1
SCHEMBL12911795 0.71 HSD11B1 (0.50) HSD11B1DRD2KMT2ATSHRL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7465744-B2 Triazole compounds and the therapeutic use thereof ABBOTT GMBH & CO. KG (DE) 2008-12-16 US disclosed
EP-1594861-B1 TRIAZOLE COMPOUNDS AND THE THERAPEUTIC USE THEREOF ABBOTT GMBH & CO KG (DE) 2008-06-18 EP disclosed
US-20060241137-A1 Dopamine-D3-receptor antagonists/agonists; high selectivity, bioavailability and high cerebral availability; central nervous system diorders; 2-{3-[(4-methyl-5-phenyl-4H-1,2,4-triazol-3-yl)thio]propyl}-7-propionyl-1,2,3,4-tetrahydroisoquinoline ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2006-10-26 US disclosed
EP-1594861-A1 TRIAZOLE COMPOUNDS AND THE THERAPEUTIC USE THEREOF Abbott GmbH & Co. KG (DE) 2005-11-16 EP disclosed
WO-2004069830-A1 TRIAZOLE COMPOUNDS AND THE THERAPEUTIC USE THEREOF ABBOTT GMBH & CO. KG (DE) 2004-08-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060241137-A1 Dopamine-D3-receptor antagonists/agonists; high selectivity, bioavailability and high cerebral availability; central nervous system diorders; 2-{3-[(4-methyl-5-phenyl-4H-1,2,4-triazol-3-yl)thio]propyl}-7-propionyl-1,2,3,4-tetrahydroisoquinoline DRD3, SLC6A3, ADORA3 HSD11B1 1302/4885DRD2 4/4885KMT2A 2678/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.